Gilberto Fronza

List of Publications by Year
in descending order

96	2,050	236612	288905
papers	citations	25 h-index	40 g-index

97	97	97	2555
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. Blood Advances, 2022, 6, 5593-5612.	2.5	3
2	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	1.1	5
3	MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome. MicroRNA (Shariqah, United Arab Emirates), 2021, 9, 322-335.	0.6	1
4	Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay. Genes, 2021, 12, 277.	1.0	6
5	Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 107.	1.1	7
6	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	2.0	8
7	TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 5566-5575.	3.2	23
8	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	1.3	6
9	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. Cells, 2021, 10, 98.	1.8	23
10	SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129440.	1.1	13
11	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. Frontiers in Oncology, 2020, 10, 593383.	1.3	50
12	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. Scientific Reports, 2020, 10, 18427.	1.6	13
13	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	2.8	7
14	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opinion on Investigational Drugs, 2020, 29, 869-880.	1.9	10
15	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. Non-coding RNA, 2020, 6, 11.	1.3	11
16	Yeast As a Chassis for Developing Functional Assays to Study Human P53. Journal of Visualized Experiments, 2019, , .	0.2	9
17	Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival. Bioscience Reports, 2019, 39, .	1.1	37
18	P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. Bioscience Reports, 2019, 39, .	1.1	5

#	Article	IF	Citations
19	Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Scientific Reports, 2018, 8, 13762.	1.6	29
20	Gambogic acid counteracts mutant p53 stability by inducing autophagy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 382-392.	1.9	24
21	TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. Oncology Reports, 2017, 38, 1985-1994.	1.2	12
22	Human transcription factors in yeast: the fruitful examples of P53 and NF-ÐºB. FEMS Yeast Research, 2016, 16, fow083.	1.1	6
23	The <scp>CDKN</scp>2A/p16<scp>^{INK}</scp>^{4a} 5â€²<scp>UTR</scp> sequence and translational regulation: impact of novel variants predisposing to melanoma. Pigment Cell and Melanoma Research, 2016, 29, 210-221.	1.5	9
24	Abstract 2883: Impact of novel CDKN2A/p16INK4a 5â€™UTR variants predisposing to melanoma on p16 translational regulation. , 2016, , .		0
25	Studying p53 family proteins in yeast: Induction of autophagic cell death and modulation by interactors and small molecules. Experimental Cell Research, 2015, 330, 164-177.	1.2	11
26	TP53 Mutants in the Tower of Babel of Cancer Progression. Human Mutation, 2014, 35, 689-701.	1.1	39
27	Structural Studies on Mechanisms to Activate Mutant p53. Sub-Cellular Biochemistry, 2014, 85, 119-132.	1.0	9
28	Comparison of the biological effects of MMS and Me-lex, a minor groove methylating agent: Clarifying the role of N3-methyladenine. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 759, 45-51.	0.4	3
29	Î”N-P63Î± and TA-P63Î± exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. Oncotarget, 2014, 5, 2116-2130.	0.8	25
30	Abstract 3402: Î”N-p63Î± and TA-p63Î± exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites. , 2014, , .		0
31	EEC- and ADULT-AssociatedTP63Mutations Exhibit Functional Heterogeneity Toward P63 Responsive Sequences. Human Mutation, 2013, 34, 894-904.	1.1	19
32	PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1904-1913.	1.9	24
33	Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Research, 2013, 41, 8637-8653.	6.5	41
34	The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Research, 2013, 41, D962-D969.	6.5	138
35	P53 Family Members Modulate the Expression of PRODH, but Not PRODH2, via Intronic p53 Response Elements. PLoS ONE, 2013, 8, e69152.	1.1	29
36	Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6066-6071.	3.3	41

#	Article	IF	Citations
37	p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System. PLoS ONE, 2011, 6, e20643.	1.1	43
38	3-Methyl-3-deazaadenine, a stable isostere of N3-methyl-adenine, is efficiently bypassed by replication in vivo and by transcription in vitro. DNA Repair, 2011, 10, 861-868.	1.3	7
39	Dominant-Negative Features of Mutant TP53 in Germline Carriers Have Limited Impact on Cancer Outcomes. Molecular Cancer Research, 2011, 9, 271-279.	1.5	66
40	Mutagenicity of N3-methyladenine: A multi-translesion polymerase affair. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 683, 50-56.	0.4	20
41	XRCC1 deficiency influences the cytotoxicity and the genomic instability induced by Me-lex, a specific inducer of N3-methyladenine. DNA Repair, 2010, 9, 728-736.	1.3	1
42	MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma. Pediatric Blood and Cancer, 2010, 55, 267-272.	0.8	5
43	Effect of N3-Methyladenine and an Isosteric Stable Analogue on DNA Polymerization. Journal of Nucleic Acids, 2010, 2010, 1-14.	0.8	6
44	PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochemical and Biophysical Research Communications, 2010, 402, 345-350.	1.0	21
45	High frequency of genomic deletions induced by Me-lex, a sequence selective N3-adenine methylating agent, at the Hprt locus in Chinese hamster ovary cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 671, 58-66.	0.4	5
46	Identification of a novel TP53 germline mutation in a large Italian Liâ€"Fraumeni syndrome Family. Pediatric Blood and Cancer, 2009, 52, 303-304.	0.8	0
47	MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatric Blood and Cancer, 2009, 53, 576-583.	0.8	17
48	PRIMAâ€1 synergizes with adriamycin to induce cell death in nonâ€small cell lung cancer cells. Journal of Cellular Biochemistry, 2008, 104, 2363-2373.	1.2	29
49	Rev1 and Polζ influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent. DNA Repair, 2008, 7, 431-438.	1.3	14
50	Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma. European Journal of Cancer, 2008, 44, 2634-2639.	1.3	17
51	Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach. Mutagenesis, 2007, 22, 417-423.	1.0	4
52	Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype. Clinical Cancer Research, 2007, 13, 3789-3795.	3.2	48
53	The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage. Journal of Cellular Biochemistry, 2007, 100, 1276-1287.	1.2	12
54	Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function. Journal of Cellular Biochemistry, 2006, 98, 1689-1700.	1.2	4

#	Article	IF	Citations
55	Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the p53 PIN3 A2-Pro72 Haplotype. Digestion, 2006, 74, 228-235.	1.2	19
56	Involvement of human p53 in induced intrachromosomal recombination in Saccharomyces cerevisiae. Mutagenesis, 2004, 19, 333-339.	1.0	7
57	The biological effects of N3-methyladenine. Journal of Cellular Biochemistry, 2004, 91, 250-257.	1.2	49
58	Nucleotide Excision Repair Defect Influences Lethality and Mutagenicity Induced by Me-lex, a Sequence-Selective N3-Adenine Methylating Agent in the Absence of Base Excision Repair. Biochemistry, 2004, 43, 5592-5599.	1.2	18
59	Characterization of the p53 mutants ability to inhibit p73Î² transactivation using a yeast-based functional assay. Oncogene, 2003, 22, 5252-5260.	2.6	43
60	DNA Damage and Cytotoxicity Induced by Minor Groove Binding Methyl Sulfonate Estersâ€. Biochemistry, 2003, 42, 14318-14327.	1.2	23
61	Influences of Base Excision Repair Defects on the Lethality and Mutagenicity Induced by Me-lex, a Sequence-selective N3-Adenine Methylating Agent. Journal of Biological Chemistry, 2002, 277, 28663-28668.	1.6	18
62	Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene, 2002, 21, 1641-1648.	2.6	61
63	Evidence inEscherichia colithat N3-Methyladenine Lesions Induced by a Minor Groove Binding Methyl Sulfonate Ester Can Be Processed by both Base and Nucleotide Excision Repairâ€. Biochemistry, 2001, 40, 1796-1803.	1.2	25
64	Partial characterization ofSUVi, a new mammalian gene induced by UV-c and expressed during the S phase of the cell cycle. Environmental and Molecular Mutagenesis, 2001, 37, 76-84.	0.9	3
65	p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene, 2001, 20, 501-513.	2.6	55
66	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene, 2001, 20, 3533-3540.	2.6	57
67	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene, 2001, 20, 3573-3579.	2.6	125
68	Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. International Journal of Cancer, 2000, 88, 744-750.	2.3	7
69	Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification. Carcinogenesis, 2000, 21, 1631-1638.	1.3	8
70	p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis, 2000, 15, 127-132.	1.0	13
71	Multiple mutations and frameshifts are the hallmark of defective hPMS2 in pZ189-transfected human tumor cells. Nucleic Acids Research, 2000, 28, 2577-2584.	6.5	9
72	The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutation Research - Reviews in Mutation Research, 2000, 462, 293-301.	2.4	29

#	Article	IF	Citations
73	Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent. Journal of Biological Chemistry, 1999, 274, 18327-18334.	1.6	39
74	Derivative Chromosome 17 in a Case of Burkitt Lymphoma with 8;14 Translocation. Cancer Genetics and Cytogenetics, 1999, 110, 1-6.	1.0	0
75	5-Methylcytosine at HpaII sites in p53 is not hypermutable after UVC irradiation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 431, 93-103.	0.4	9
76	Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis, 1998, 19, 741-746.	1.3	31
77	p53 Mutations and DNA Ploidy in Colorectal Adenocarcinomas. Analytical Cellular Pathology, 1998, 17, 1-12.	2.1	14
78	Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis, 1997, 18, 2019-2021.	1.3	41
79	Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology. Oncogene, 1997, 14, 1307-1313.	2.6	39
80	Mutational specificity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea inEscherichia coli: Comparison of in vivo with in vitro exposure of thesupF gene. , 1997, 30, 65-71.		2
81	Mutation spectra analysis suggests that N-(2-chloroethyl)-Nâ€²-cyclohexyl-N-nitrosourea-induced lesions are subject to transcription-coupled repair in Escherichia coli. , 1997, 19, 39-45.		3
82	Heterogeneousp53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonalc-myc andVDJ rearrangements. , 1997, 73, 816-821.		6
83	Study on aneuploidy and p53 mutations in astrocytonias. Cancer Genetics and Cytogenetics, 1996, 88, 95-102.	1.0	19
84	Concentration-dependent mutational hotspots induced by the antineoplastic drug chloroethyl-cyclohexyl-nitroso-urea in mammalian cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 352, 47-49.	0.4	0
85	Lack of mutations in K-ras codons 12 and 13 in human atherosclerotic lesions. Chemico-Biological Interactions, 1996, 102, 55-62.	1.7	5
86	DNA adducts and chronic degenerative diseases. Pathogenetic relevance and implications in preventive medicine. Mutation Research - Reviews in Genetic Toxicology, 1996, 366, 197-238.	3.0	124
87	The ultimate carcinogen of 4-nitroquinoline 1-oxide does not react with Z-DNA and hyperreacts with B-Z junctions. Nucleic Acids Research, 1994, 22, 314-320.	6.5	20
88	Mutation spectrum of 4-nitroquinoline 1-oxide-damaged single-stranded shuttle vector DNA transfected into monkey cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 308, 117-125.	0.4	8
89	Defective splicing induced by 4NQO in the hamster hprt gene. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 323, 159-165.	1.2	11
90	Analysis of 4-nitroquinoline-1-oxide induced mutations at the hprt locus in mammalian cells: possible involvement of preferential DNA repair. Mutagenesis, 1994, 9, 67-72.	1.0	21

#	Article	IF	Citations
91	The 4-nitroquinoline 1-oxide mutational spectrum in single stranded DNA is characterized by guanine to pyrimidine transversions. Nucleic Acids Research, 1992, 20, 1283-1287.	6.5	40
92	4-NQO mutational spectrum in ssDNA reveals a correlation between the C8 guanine adduct and G to Pyr transversions. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1992, 271, 151.	0.4	0
93	4-Acetoxyaminoquinoline-1-oxide-induced mutations in the ssM13lacZ' phage DNA. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1991, 252, 203-204.	0.4	0
94	Extent of helix perturbation associated with DNA modification by the o-acetyl derivative of the carcinogen 4-hydroxyaminoquinoline-1-oxide. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1990, 1087, 330-335.	2.4	3
95	In vitro DNA modification by the ultimate carcinogen of 4-nitroquinoline-1-oxide: influence of superhelicity. Carcinogenesis, 1989, 10, 1589-1593.	1.3	31
96	Interaction between supercoiled DNA and the o-acetyl derivative of the carcinogen 4-nitroquinoline 1-oxide. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 181, 337.	0.4	0